Wall Street brokerages expect that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will report earnings of ($0.45) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.43) and the lowest estimate coming in at ($0.49). Syros Pharmaceuticals reported earnings of ($0.53) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.1%. The company is expected to report its next quarterly earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.85) per share for the current year, with EPS estimates ranging from ($1.92) to ($1.77). For the next financial year, analysts anticipate that the company will post earnings of ($1.93) per share, with EPS estimates ranging from ($2.12) to ($1.67). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Friday, August 10th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.07. The business had revenue of $0.38 million during the quarter, compared to the consensus estimate of $1.33 million.

A number of equities analysts have recently commented on SYRS shares. Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Tuesday, July 17th. BidaskClub lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, July 26th. Zacks Investment Research lowered Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Cann reiterated a “buy” rating and issued a $26.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, August 7th. Finally, ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 6th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $21.00.

A number of institutional investors and hedge funds have recently modified their holdings of SYRS. Redmile Group LLC increased its stake in Syros Pharmaceuticals by 159.3% during the first quarter. Redmile Group LLC now owns 1,652,240 shares of the company’s stock valued at $21,446,000 after acquiring an additional 1,015,008 shares during the period. BlackRock Inc. increased its stake in Syros Pharmaceuticals by 70.4% during the second quarter. BlackRock Inc. now owns 1,583,631 shares of the company’s stock valued at $16,169,000 after acquiring an additional 654,094 shares during the period. ARK Investment Management LLC increased its stake in Syros Pharmaceuticals by 19.6% during the second quarter. ARK Investment Management LLC now owns 1,799,553 shares of the company’s stock valued at $18,373,000 after acquiring an additional 294,663 shares during the period. Millennium Management LLC increased its stake in Syros Pharmaceuticals by 129.3% during the second quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock valued at $3,834,000 after acquiring an additional 211,696 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in Syros Pharmaceuticals during the second quarter valued at about $1,703,000. Hedge funds and other institutional investors own 60.70% of the company’s stock.

Syros Pharmaceuticals stock opened at $11.76 on Friday. The stock has a market capitalization of $402.51 million, a PE ratio of -5.52 and a beta of -2.06. Syros Pharmaceuticals has a 52 week low of $6.30 and a 52 week high of $17.89.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Read More: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.